2 November 2009 - BAC BV has entered into a licence agreement with Octapharma to use BAC's anti-Factor IX CaptureSelect affinity ligand in the large-scale purification of recombinant Factor IX (FIX).
The companies have embarked on a discovery programme under which BAC will develop a CaptureSelect affinity ligand for the purification of recombinant human granulocyte-colony stimulating factor (G-CSF), which has applications in oncology and haematology.
Under the terms of the FIX agreement Octapharma will have licence to use BAC's anti-FIX ligand for the purification of FIX from mammalian cell culture.
Under the terms of the G-CSF agreement, BAC will perform ligand discovery and development to provide an anti-G-CSF ligand, which will then undergo feasibility studies at Octapharma.
